Table 4.

Key unanswered questions for women considering progestin treatment for their endometrial cancer.

Which tumors will have a complete pathological response? What are the optimum type, dose and duration of progestin treatment? What are the optimum duration and frequency of follow-up after achieving a pathological complete response? Should progestin treatment be continued after achieving a pathological complete response and if so, for how long? Should progestin treatment be continued after a partial or failed response and if so, for how long? What are the criteria for stopping progestin treatment? Is a hysterectomy necessary after completing childbearing? Should dual-agent therapy be administered (eg. metformin, weight loss, targeted therapy) and if so, which patients would benefit? Can MMR-deficient tumors due to germline MMR mutation(s) be treated similarly to tumors with somatic MMR modifications? How can emerging molecular data best be incorporated into patient management?